Sarcoidosis is a multisystem disorder characterized by the formation of granulomatous inflammatory nodules mainly located in the lungs, lymphatic system, skin and eyes. In patients with pulmonary involvement, targeting IFN-γ has proven ineffective. Researchers from Baylor College of Medicine and collaborators reported on the use of nonreceptor tyrosine phosphatase Src homolog-2 domain-containing phosphatase 2 (SHP2) inhibition as a potential strategy to treat sarcoidosis-like diseases.